There’s no therapy developed yet, that can stop cancer cells from moving throughout the body. New research shows that it may be possible to do so, in freezing cancer cells and killing them where they stand.
Genomics will change what patients expect from their provider, as well as change how physicians treat them. Before this happens, education on both sides is needed. This month we look at some of the big talking points.
Scientists seeking to unlock secrets of cellular ageing have identified a gene that triggers senescence, a phenomenon in which cells stop dividing.
Psychiatric disorders share many genetic variants, while neurological disorders appear more distinct, according to a new study from the Brainstorm Consortium.
A survey of people who have taken part in clinical trials indicates that participants care more about the benefits to science than the risk of sharing their personal data.
We’d all dearly like to see a cure for the common cold, but it never quite seems to arrive. So what’s the hold-up — and will it be over soon? Getting rid of this scourge is nothing to be sneezed at.
Computational researchers have developed a computer program which has revealed a previously unknown combination of drugs that may be the answer to triple-negative breast cancer.
Travel allows us to see the world – and bring foreign diseases home. Here’s why spreading disease is easier than ever.
Researchers from the Mayo Clinic recommends genetic testing for all pancreatic cancer patients as the new standard of care, after finding six genetic mutations in patients with no family history of the disease.
When it comes to understanding what makes people tick—and get sick—medical science has long assumed that the bigger the sample of human subjects, the better. New research suggests this big data approach may be wildly off the mark.
The Wellcome Sanger Institute has provided evidence and made recommendations for an inquiry by the UK Parliament Science and Technology Committee into an immigration system that works for science and innovation, following Brexit.
Researchers have identified a new subtype of prostate cancer that occurs in about 7% of patients with advanced disease. This subset of tumours was responsive to immunotherapy treatment.